TME Pharma Secures 12-Month Loan Extension, Extends Cash Runway to Q2 2027
Key Insights
TME Pharma (search) successfully negotiated a 12-month extension on €2.06M in loans from lenders, representing 93.2% of its May and August 2025 fundraising debt.
The company now has financial runway extending into Q2 2027, providing crucial time to advance partnership discussions for its lead cancer and eye disease therapies.
Lenders received 30% additional warrants with extended terms until December 2030, potentially generating €678k in additional funding if fully exercised.
TME Pharma (search) N.V., a clinical-stage biotechnology company developing novel therapies for cancer and eye diseases (search), announced on March 9, 2025, that it has successfully extended the maturity of loans totaling approximately €2.06M by 12 months, extending its cash runway into Q2 2027.
Loan Extension Details
The agreement covers 93.2% of the total loans from the company's May and August 2025 fundraising rounds, with participating lenders including board members and CEO Diede van den Ouden. In consideration for the 12-month extension, warrant terms have been extended until December 31, 2030, and lenders received 30% additional warrants at the same strike prices as existing warrants (€0.10 and €0.11 respectively).
The additional warrants are subject to a lock-up period until January 1, 2029, unless the share price reaches €0.25 or higher. If all new warrants under the amended agreements are exercised, TME Pharma (search) could receive approximately €678k in additional funding through the issuance of 6,584,116 shares, representing approximately 7% dilution.
TME Pharma (search) will redeem bonds early on March 11 to bondholders who declined the extension, totaling €163,562.50 including interest.
Management Commentary
"I am delighted that TME Pharma (search) and its shareholders have once again earned the trust of its investors," said CEO Diede van den Ouden. "This demonstrates the lenders' confidence in the company and its management to achieve success. Now that TME Pharma has secured further financial stability, management can accelerate its discussions with partners to optimize the value of NOX-A12 and NOX-36."
Lead Drug Candidates
TME Pharma (search)'s pipeline focuses on compounds designed to act on the tumor microenvironment and cancer immunity cycle. The company's two lead assets are:
NOX-A12 (olaptesed pegol) is an anti-CXCL12 (search) L-RNA aptamer currently being studied in the GLORIA Phase 1/2 clinical trial for newly-diagnosed brain cancer (search) patients who will not benefit from standard chemotherapy. The FDA and German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma (search), and TME Pharma (search) received Fast Track Designation from the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for glioblastoma treatment. The compound also holds orphan drug designation for glioblastoma in the United States and glioma in Europe.
NOX-E36 (emapticap pegol) is an L-RNA aptamer inhibiting CCL2 (search) and related chemokines, being evaluated in ophthalmic diseases (search) requiring well-tolerated therapies with anti-fibrotic effects.
Strategic Restructuring Initiatives
Under van den Ouden's leadership since June 2025, TME Pharma (search) is implementing a strategic restructuring to unlock value from its lead compounds. The initiatives include raising €1.7 million in May 2025 (including €500,000 from the CEO), pursuing cash-generating business opportunities, leveraging tax loss carry forwards, and potentially gaining exposure to digital assets.
The company is also exploring acquisitions and partnerships in stable, profitable businesses to create a fundamentally profitable corporate structure where non-core revenues support continued development of NOX-A12 and NOX-E36.
Clinical Trial Programs
The GLORIA study (NCT04121455) is a dose-escalation Phase 1/2 trial evaluating NOX-A12 combined with radiotherapy in first-line partially resected or unresected glioblastoma (search) patients with unmethylated MGMT promoter. The expansion arm combines NOX-A12 with radiotherapy and bevacizumab.
The planned OPTIMUS study (NCT04901741) is an open-label two-arm Phase 2 trial of NOX-A12 combined with pembrolizumab and either nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer (search) patients.
TME Pharma (search) maintains that only 3,130 new shares from warrant exercises have been issued since January 1, 2025, with no warrants from the May and August 2025 loans currently exercised. The company has not issued additional shares in 2025 and 2026, focusing on shareholder value creation.